Kornimate/medical-research-clean huggingface dataset:
fluzoparib combined with dalpiciclib for platinum resistant recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: this study aims to investigate the safety and efficacy of combination therapy of fluzoparib combined with dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase ii clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.

1. overall design: this trial is a single-center, prospective, single-arm, phase ii clinical trial to evaluate the safety and efficacy of combination therapy of fluzoparib combined with dalpiciclib for platinum-resistant recurrent ovarian cancer. 2. experimental observation indicators: 1) main indicators: progression-free survival (pfs), 2) other indicators: overall survival (os), objective response rate (orr), and adverse reactions. 3. sample size calculation: the median pfs of platinum-resistant recurrent ovarian cancer patients is 3.8 months. in comparison, the experimental group is expected to have a median pfs of 7 months, with an alpha value of 0.05. following up for 1 year and considering a 10% dropout rate, this study plans to include 30 platinum-resistant recurrent ovarian cancer patients. 4. data processing: enter data and use spss statistical software for statistical analysis. statistical analyst: clinical statistics department of fudan university cancer hospital. mailing address: 270 dong'an road, shanghai.

Eligibility criteria:
inclusion criteria: 1. age≥18 years old; 2. sign the informed consent form; 3. histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer. 4. tumor recurrence or progression within 6 months after using platinum-based drugs; exclusion criteria: 1. any uncontrolled medical condition that may put the patient at high risk during treatment . 2. receipt of any other investigational medicinal product within the last 30 days before randomization. 3. patients with ovarian cancer excluded by pathological or clinical diagnosis; 4. physical intolerance patients; 5. patients who are unwilling to participate in the clinical trial.

Keywords: ovarian cancer platinum resistance fluzoparib dalpiciclib
comparison of routine and core-stability exercises on dynamic sitting balance and trunk control in stroke patients

Conditions: Ischemic Stroke, Acute

Summary: this is rom trail study. data collected from rabbani hospital lahore . in this study total two groups included control and experimental and sample size was 48 and 24 persons divided in each groups as well. informed consent was taken from the recruited subjects. two scales bbs and tis used to measure the outcomes. data analyse by ssps v21.0 with a significant level of p valued 0.05. results were in the favour of experimental group.

this is rom trail study. data collected from physiotherapy department of rabbani hospital lahore . in this study total two groups included control and experimental and sample size was 48 and 24 persons randomly allocated in each groups as well. in control group conventional therapy given while in experimental group core-stability exercises with conventional therapy given to the patients. while the duration of therapy was 45 minutes per day for 8 weeks. informed consent was taken from the recruited subjects. two scales bbs and tis used to measure the outcomes. only having first episode of sub-acute stoke patients and diagnosed by neuro-physician were included in study. data entered and analysed by ssps v21.0 with a significant level of p valued 0.05. and the results were in the favour of study means experimental group.

Eligibility criteria:
* inclusion criteria: * sub-acute ischemic and stroke diagnosed by neuro-physican having 1st episode * patients in sub-acute stage (2-12 weeks) * patients who can follow the instruction according to mini mental scale \< 7 * minimum score of a patient on burg balance and trunk impairment scale to enter in rehab unit and include in any research i-e tis \< 2 in scoring and bbs \< 4 minimum scoring. * exclusion criteria: * recurrent stroke * subjects with radiating pain or nerve root involvement * diagnosed by any neurological condition other than stroke, or other clinical comorbidity that affect the trunk balance. * patient unable to follow the instructions * comprehension deficits that prevented them from following verbal commands * unconscious patient
the effect of sedation on rebound pain in knee arthroplasty

Conditions: Total Knee Arthroplasty; Sedation

Summary: dexmedetomidine is often used for sedation procedures. it has also been shown to have a pain-protective effect. researchers predicted that using dexmedetomidine for sedation in total knee arthroplasties performed under spinal anesthesia would reduce the frequency of rebound pain and pain scores.

randomization will take place before the patient enters the operating room. after spinal anesthesia is applied, 0.4 mcg/kg sedadomide loading will be done for 10 minutes in the sedation group, and then 0.4 mcg/kg/h sedadomide infusion will continue until the end of the surgery. patients selected for the control group will be given the same amounts of saline. at the end of the surgical procedure, saline and sedadomide infusions will be stopped. all patients will undergo an adductor canal block under usg guidance in the recovery room. 50 mg of buvacin will be given to the block area. patients will be fitted with a patient control analgesia device, which only provides bolus application and provides 20 mg of madol in each bolus. postoperatively, sudden onset severe withdrawal pain outside the normal course of pain starting within 48 hours will be followed and vas-bromage monitoring will be done at 0, 1, 2, 4, 8, 12, 24, 36, 48 hours.

Eligibility criteria:
inclusion criteria: * total knee arthroplasty american society of anesthesiologist score of 1-3 age 18-85 elective total knee arthroplasty under spinal anesthetic. exclusion criteria: * situations in which spinal anesthesia is contraindicated * advanced organ failure states(cardiac,hepatic,respiratuar or renal) * pregnancy * bmi \> 40 kg/m\^2 * do not want to participate in the study * younger than 18 or older than 85 * have bilateral total knee arthroplasty or resurgery * develop an unexpected intraoperative surgical complication
validation of a dance as therapy program in co-facilitation

Conditions: Trauma, Psychological; Depression, Anxiety; Stress; Body Image; Quality of Life; Social Relationship; Attachment Disorder

Summary: the objective is to validate a psychotherapeutic group protocol of dance as therapy created by loba association with a comparative non-randomized study.

this present research is a prospective longitudinal monocentric comparative study of an alternative, non-pharmacological therapy. it is a controlled, non-randomized, and experimental study in which half of the participants benefit from an additional program with speech and movement co-therapy via body activity, and the other half only benefit from standard support (e.g. medical, social, and legal assistance, individual psychotherapy). the effect of this program will be examined across three dimensions: * a clinical trial of n=80 participants to compare symptom improvement between individuals receiving the standard support for victims of sexual violence (n=40) and those receiving, in addition, the recreation program (n=40). * a longitudinal evaluation of physiological conditions, psychological traits, and social well-being of recreation workshop attendees (n=10) versus victims not participating in said workshops (n=10). * a qualitative analysis of interviews with program participants and their associated professionals (data saturation sample size).

Eligibility criteria:
inclusion criteria: * french-speaking * woman * over 18 years old * victim of sexual violence exclusion criteria: * non-french-speaking person, * under 18 years old * not woman * not victim of sexual violence

Keywords: sexual violence trauma psychotherapy dance as therapy longitudinal study attachment mentalization
proton radiation therapy for gliomas

Conditions: Low Grade Glioma; WHO Grade 3 Glioma With IDH1 Mutation; WHO Grade 3 Glioma With 1p/19q Codeletion

Summary: in this research study the investigators are looking at a type of radiation called proton radiation. proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. this may reduce side effects that patients would normally experience with conventional radiation therapy. in this research study the investigators are looking to determine if proton radiation with a reduced field size will be as effective in controlling tumor growth as photon therapy, while reducing the treatment-related side effects observed in patients with brain tumors.

proton radiation will be delivered daily for approximately 6 weeks. subjects will be assessed weekly for side effects. each visit will take about 15 minutes. subjects will have follow-up visits at 3, 6, 12, 24, 36, 48, 60, 72, and 84 months after their last proton radiation treatment. they will receive a physical exam, mri, have blood tests (about 4 teaspoons) and answer questionnaires regarding medical history, quality of life, and emotional well-being. subjects will also receive a neurocognitive exam annually.

Eligibility criteria:
inclusion criteria: * histologically confirmed low-grade gliomas or grade iii anaplastic glioma with either or both idh1 mutation or 1p/19q codeletion * subject must be indicated for radiation therapy * life expectancy greater than 5 years * willing to participate in rigorous neurocognitive evaluations at baseline and serially following treatment * able to speak and comprehend english * recovered from adverse events due to agents administered more than 4 weeks before entering study * able to undergo mri scans exclusion criteria: * prior cranial radiation therapy * chemotherapy within 4 weeks prior to entering study * pregnant or breastfeeding * known brain metastases * baseline neurocognitive or emotional disorders * uncontrolled intercurrent illness * history of a different malignancy unless disease-free for at least 5 years * hiv positive on antiretroviral therapy

Keywords: brain tumors radiation proton gliomas
ellume·lab flu a+b test and the ellume home flu test performance versus viral culture and reverse transcriptase polymerase chain reaction

Conditions: Influenza

Summary: the primary purpose of the study is to validate the sensitivity and specificity of the ellume home flu test and the ellume.lab flu a+b test in detecting influenza a and influenza b as compared to reverse transcriptase polymerase chain reaction (rt-pcr) secondary aims are to: validate the sensitivity and specificity of the ellume home flu test and the ellume.lab flu a+b test in detecting influenza a and influenza b as compared to viral culture; evaluate the participant's satisfaction with the convenience and ease of use of the ellume home flu test; evaluate the participant's interpretation of the ellume home flu test results compared to the interpretation by site staff; evaluate the operator's satisfaction and ease of use of the ellume·lab flu a+b test.


Eligibility criteria:
inclusion criteria: * male and female participants aged ≥ 2 years; and * fever ≥ 37.8° c (100° f) at presentation or history or parent/guardian-reported history of fever ≥ 37.8° c or feeling feverish within 24 hours of presentation; and * rhinorrhea; and * ≤ 72 hours from onset of ili symptoms; and * participant (or parent/legal guardian) capable and willing to give informed consent/assent; and * participant (or parent/legal guardian) able to read and write in english. exclusion criteria: * participants aged \< 2 years. * participants who have undergone treatment with tamiflu (oseltamivir), relenza (zanamivir) or symmetral (amantadine) within the previous 7 days; * participants who have been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days; * participants who have had a nose bleed within the past 30 days; * participants who have had recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months; * participants currently enrolled in another clinical trial or used any investigational device within 30 days preceding informed consent. * participants previously enrolled in ie-flu-aus-1801; * participants 18 years of age or older unable to understand english and consent to participation; * parent/legal guardian of participants \< 18 years of age unable to understand english and consent to participation of child.
effects of hippotherapy on functionality in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this clinical review is to investigate the effect of hippotherapy in improving upper limb functionality in children with cerebral palsy. the main question it aims to answer is the questions are as follows: 1. does hippotherapy improve gross motor function of the upper extremity in children with cerebral palsy? 2. is the development of trunk control in children with cerebral palsy who receive hippotherapy different from the development of trunk control in children who receive conventional physiotherapy? participants will: hippotherapy and routine physiotherapy in 2 different groups for 2 they will carry out the necessary evaluations before the implementation and at the end of 2 months.

cerebral palsy (cp) is a permanent developmental disorder that occurs as a result of a lesion in the developing baby's brain. due to the symptoms seen in cp, the individual's participation in daily living activities (adl) is restricted and functional mobility is affected. hippotherapy is preferred in children with cp because it includes fun activities and is effective in terms of the child's participation and motivation. the aim of this study is to examine the effect of hippotherapy on upper extremity function. in this study planned as a multicenter study, children with cp are divided into 2 groups as the study and control groups. after a 2-month application, children with cp will be evaluated in terms of upper extremity functionality and postural control. the "statistical package for social sciences (spss) statistics 23.0 (spss inc, chicago, usa) program will be used in the analysis of the study data. the change in numerical variables over time in the treatment and control groups and the group-time interaction will be examined with "two-way repeated measures variance analysis". the "chi-square test" will be used to examine the relationship between categorical variables. the relationship between numerical variables will be examined with the "spearman rho correlation coefficient". the probability of error will be accepted as (p\<0.05).

Eligibility criteria:
inclusion criteria: * having been diagnosed with sp * being between the ages of 4-16 * being at gmfcs (gross motor function classification system) level 1,2 or 3 * being at macs (the manual ability classification system) level 1,2,3 or 4 * having a stable clinical condition * having the cognitive level to follow the instructions in the test and treatment protocol exclusion criteria: * families who do not sign the consent form * presence of active seizures * presence of developmental hip dysplasia * presence of allergy to horses * having undergone surgical intervention or botulinum toxin a (btx-a) application in the last 6 months

Keywords: hippotherapy physiotherapy cerebral palsy
diaphragmatic function description in stroke patients

Conditions: Stroke; Diaphragmatic Function

Summary: stroke is the leading cause of adult disability throughout the world. motor function deficit is one of the common consequences. it is usually described for the peripheral muscles that there is a cortical representation contralaterale with a crossed cortico-spinal route: the consequence is a contralaterale motor disorder on the brain damage. the impact of a stroke on diaphragm movements have been described in 6 studies: however, they were all observational and transversal studies evaluating diaphragm function. assessment using diaphragm thickness is another technique described in the literature. visualization of diaphragm in the zone of apposition allows to assess diaphragm thickness at inspiration and expiration. the impact of a stroke on diaphragm thickening has been reported in only one recent observational study. it seems that diaphragm would be damaged after a stroke, but unilateral or bilateral dysfonction is yet to be confirmed. moreover, only a few measurements were performed in these studies, and not a diaphragm function follow-up.

to our knowledge, no longitudinal study evaluated diaphragm movements and diaphragm thickness fraction. this study is a preliminary study which aims to evaluate diaphragm function after a stroke and its evaluation within the first months. starting hypothesis is the following: after a stroke, patients with a unilateral motor dysfunction have a diaphragm dysfunction predominant on the same side as the motor dysfunction. after a few months, retrieval is insufficient and they could benefit from a specific reinforcement program.

Eligibility criteria:
inclusion criteria: * men and women (age ≥ 18 years), hospitalized in the neuro-vascular or neurology department of the groupe hospitalier paris saint-joseph * first episode of ischemic or hemorrhagic stroke diagnosed in the imaging and responsible for a unilateral motor deficit * minimum national institute of health stroke score of 5 for the total of items 4, 5 and 6 (paralysis facial and functioning of upper and lower limbs) * patient with medical insurance * francophone exclusion criteria: * history of neuromusclar pathology * history of severe chronic respiratory pathology * malformation, chronic lesion or surgery of the diaphragm * recent thoracic and abdominal surgery * national institute of health stroke score \> 20 * limiting health care or life support patient * impossibility to understand and to make simple orders (whatever is the cause: change of consciousness, cognitive disorders, aphasias, etc...) * major handicap before stroke (rankin modified score) * refusal to participate in the study * patient under guardianship or curatorship * patient deprived of liberty
analyze sleep stages by portable ecg device

Conditions: Obstructive Sleep Apnea

Summary: sleep is a fundamental need for human and is associated with the working performance and the disease occurrence. furthermore, the amount of people with sleep disorder or apnea increased largely. thus, the analysis of sleep stages and the measurement of sleep quality became more important recently. in clinical settings, the analysis of daily sleep quality depends on actigraphy and sleep log. however, the uses of actigraphy and sleep log are not really convenient for patients. in this trial, the investigators will measure the subjects' ecg signal and movement using a portable ecg device with motion sensor. on the other hand, the sleep stages are also obtained from the current wide-established measurement- polysomnography. the ecg signals, movements, and sleep stages will be analyzed by our algorithm of artificial neural network. then, the investigators can obtain the preliminary analysis of sleep quality can be obtained by using ecg device with our algorithm. it is helpful for doctors to realize the patent's sleep quality quickly


Eligibility criteria:
inclusion criteria: * osa: opd osa patients; healthy: no osa exclusion criteria: * heart disease * arrhythmia
anesthesia for pain after ankle fracture surgery

Conditions: Chronic Pain; Ankle Fracture Surgery; Regional Anesthesia

Summary: this pilot study will test the hypothesis that prolonged regional peripheral nerve block will reduce development of chronic pain in patients undergoing surgery for ankle fracture compared to standard of care. subjects will be followed for one year.

this pilot study will test the hypothesis that prolonged regional peripheral nerve block will reduce development of chronic pain in patients undergoing surgery for ankle fracture. regional nerve block using local anesthetics delivered by ambulatory pump is used in some types of surgeries but is not routine for ankle fracture patients in our hospitals. patients will be randomized to standard care (single shot peripheral nerve block prior to surgery) or experimental (the same single shot nerve block, followed by continuous popliteal nerve block with ropivacaine starting just after surgery). the primary outcome will be scores on a validated ankle/foot pain questionnaire that includes questions on function. subjects will be followed for one year. secondary outcome will be postoperative opioid use.

Eligibility criteria:
inclusion criteria: * referred for surgery for open reduction and internal fixation for ankle fracture exclusion criteria: * unable to give informed consent in english * unable to complete surveys in english * unable to understand instructions for using pump in english * unavailable for followup * polytrauma; undergoing other surgeries or having other orthopedic injuries related to the precipitating cause of the ankle fracture * infection * peripheral vascular disease * diabetes * currently undergoing chemotherapy * pregnancy * currently lactating * heart disease or heart rhythm disorder or taking anti-arrhythmic drugs * severe renal impairment (class 3 or worse kidney disease) * liver disease (cirrhosis or liver failure) * prior allergic reaction to any type of local anesthetic * taking therapeutic doses of anti-coagulants or anti-platelet therapy (prophylactic doses started because of hospital admission are not an exclusion) * currently taking antidepressants or other psychiatric medications * single shot local nerve block prior to surgery was ineffective * selected for neuraxial anesthesia rather than general anesthesia for the open reduction surgery * already receiving chronic analgesic therapy for a separate chronic pain condition
gauss: a study of obinutuzumab (ro5072759) in patients with indolent non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: this study will investigate the efficacy of weekly intravenous obinutuzumab \[ga101 (ro5072759)\] monotherapy, in patients with relapsed cd20+ indolent non-hodgkin's lymphoma. patients will be randomized to receive either ga101 or rituximab, given as four weekly infusions. at the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. the anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age * relapsed cd20+ indolent b-cell non-hodgkin's lymphoma * documented history of response of \>/= 6 months duration from last rituximab-containing regimen * clinical indication for treatment as determined by the investigator * eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: * prior use of any investigational monoclonal antibody within 6 months of study start * prior use of any anti-cancer vaccine * prior use of rituximab within 8 weeks of study entry * radioimmunotherapy within 3 months prior to study entry * central nervous system (cns) lymphoma or evidence of transformation to high-grade or diffuse large b-cell lymphoma